Mount Sinai researchers have developed a method to uncover the hidden immune cells that harbor the human immunodeficiency ...

A clinical trial suggests Lenacapavir, a yearly injection, could revolutionise HIV prevention by offering long-term protection, simplifying adherence, and expanding access to at-risk populations., Hea ...

Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...

# Dr Forbes outlined the symptoms of common STIs, emphasising that some people may have no symptoms, making regular screening essential. Chlamydia symptoms include pain during urination, abnormal ...

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Malawians must brace for more tough times following the United Sates of America’s (USA) decision to terminate contracts worth ...

Pharma giant Gilead Sciences has revealed the results of its first, Phase 1 trial into a once-a-year PrEP injection. The ...

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...

Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...